SNY — Sanofi

Summary of Sanofi Q3 2025 Earnings Call

1. Key Financial Results and Metrics

• Sales: Q3 2025 sales reached €12.4 billion, a 7% increase year-over-year (YoY) at constant exchange rates. This growth was driven by new product launches and Dupixent's performance.
• Dupixent Sales: Dupixent achieved €4 billion in quarterly sales for the first time, marking a 26% increase YoY.
• New Launches: New product launches contributed €1.8 billion in sales, growing over 40% and accounting for 15% of total sales.
• Gross Margin: Business gross margin improved by 2.3 percentage points, attributed to a better product mix and productivity gains.
• Earnings Per Share (EPS): Business EPS grew by 13% YoY to €2.91.
• Year-to-Date Performance: Year-to-date sales growth of 9% and EPS growth of 12%.

2. Strategic Updates and Business Highlights

• New Product Launches: Successful launches included Ayvakit, Nuvaxovid, and Wayrilz, with significant uptake across the portfolio.
• Vaccine Sales: Vaccine sales were €3.4 billion, impacted by competitive pricing pressures and lower flu immunization rates in the U.S.
• Patient Affordability Initiatives: Expanded insulin affordability programs in the U.S. to improve patient access.
• Global Health Initiatives: Reached 1 million patients treated for noncommunicable diseases in low- and middle-income countries since 2021.

3. Forward Guidance and Outlook

• Full-Year Guidance: Reiterated guidance for high single-digit sales growth and low double-digit EPS growth for the full year 2025.
• 2026 Expectations: Anticipated moderate increases in R&D expenses and continued investment in sales and marketing. Projected capital gains from divestments around €0.5 billion.

4. Bad News, Challenges, or Points of Concern

• Vaccine Sales Decline: Vaccine sales were down due to competitive pressures and lower flu vaccination rates.
• Discontinuation of RSV Toddler Program: The program was halted due to unmet efficacy criteria in a planned futility analysis.
• Regulatory Challenges: Ongoing discussions with the U.S. administration regarding pricing and access policies, with concerns about potential delays or complications.
• R&D Reimbursement Reduction: Anticipated significant reductions in R&D reimbursement from Regeneron in 2027, which may impact profitability.

5. Notable Q&A Insights

• Regulatory Update on Tolebrutinib: The FDA requested additional data, with a PDUFA date set for December 28, 2025. Discussions are ongoing regarding potential subgroup approvals.
• Dupixent Pricing: The company expects net pricing dynamics to remain stable, with no specific guidance provided for year-over-year changes.
• ALTUVIIIO Market Position: The product is gaining traction as the leading switched therapy in hemophilia A, although competition remains a factor.
• Pipeline Updates: Continued focus on amlitelimab, with upcoming Phase III readouts expected to provide further insights into its efficacy and market positioning.

Overall, Sanofi demonstrated strong growth in Q3 2025, driven by Dupixent and new product launches, while facing challenges in the vaccine segment and regulatory landscape. The company remains optimistic about its future growth trajectory and pipeline advancements.